saved
Request for Proposal
Status: RFP is Closed

Transforming the Future of Tobacco Cessation & Reduction

Request Number
RFP_2019_0027
Due Date
Apr 18
Program Manager

Opportunity

GSK will award research grants, joint development opportunities, and licensing agreements with selected partners with compelling approaches that fit with GSK’s vision.

Selected partners will gain access to the GSK Smokers’ Health Leadership team for further discussions under a confidentiality agreement with the ultimate goal of funding specific projects or research initiatives.

Financials

Partner approaches will support GSK’s Nicotine Replacement Therapy (NRT) platforms.

SOLUTION PROVIDER HELP DESK USA:
 

Miss the informational webinar? Watch the recording!

RFP was closed on
Apr 2019

RFP Title

 

Transforming the Future of Tobacco Cessation & Reduction
RFP Description

NineSigma, representing GSK Consumer Healthcare, invites proposals for new technologies to ENHANCE or REIMAGINE current approaches to tobacco cessation and reduction.

Background

GSK Consumer Healthcare currently is the largest global marketer of nicotine replacement therapies (NRT) for smoking cessation. We serve patients in over 20 countries, including the US, Canada, across Europe, and Australia.

 

GSK Consumer Healthcare strives to transform the future of self-care. We hope to leverage the wisdom of experts within the fields of nicotine and tobacco research to identify areas of critical and emerging unmet needs within the tobacco cessation and reduction space and collaborate with key scientific partners to help deliver upon them.

Key Success Criteria

The challenge focuses around the following areas of interest for GSK. Those with technologies that can fit or be adapted to any of these areas are asked to submit a brief proposal through the NineSights web portal (details below).

 

Differentiated Nicotine Replacement Therapy

GSK seeks differentiated oral and transdermal dosage forms for our NRT products as part of our Smokers’ Health franchise.  Innovation may deliver superior efficacy or enhanced user experience.

 

Additionally, we are always seeking to improve how patients utilize our products by innovating in areas such as (but not limited to):

  • Cessation and reduction of Electronic Nicotine Delivery Systems (ENDS)
  • Novel dosage forms
  • Improving compliance and adherence
  • Research related to the efficacy or effectiveness of NRT
  • Increasing access and availability to NRT

 

Digital Health & Behavioral Support Platforms

Behavioral support is shown to improve a smoker’s chances of quitting. GSK is interested in connected devices and technology platforms which help consumers quit or reduce smoking as well as manage their respiratory health.  Areas of interest broadly include (but are not limited to):

 

  • Improving the delivery and efficacy of behavioral support programs through greater personalization and customization via artificial intelligence, passive data collection, etc.
  • Digital interventions that increase compliance with NRT.
  • Digital interventions that improve the health and wellness of individuals trying to quit or reduce nicotine consumption.

 

Open Ended

If you could collaborate with GSK to improve any aspect of the lives of those struggling with a nicotine addiction, what would that be and how can GSK help?

Possible Approaches

GSK notes that possible approaches might include, but are not limited to:

  • Products, features, and/or services that provide at least an incremental improvement to current offerings.
  • Current research that can inform or evolve GSK’s NRT portfolio or digital behavioral support platform.
Approaches not of Interest

Approaches that provide alternatives to smoking but do not promote a nicotine-free lifestyle are not of interest to GSK.

Items to be Submitted

Your response should address the following:

  • The AREA OF INTEREST (as listed above) which your approach addresses
  • A non-confidential description of your proposed technology and working principle
  • Availability of technical data
  • Technical maturity of the approach (concept, research, reduced to practice, prototype, ready to commercialize, ready to implement, commercialized)
  • Pathway to commercial scale including timing, estimated budget, and capacity for manufacture
  • Position on intellectual property including patent references
  • Desired relationship with GSK
  • Team description and related experience
Preferred Collaboration Types
Area of Interest